Digital CBTI for Comorbid Insomnia in Chronic Migraine
- Conditions
- Insomnia ChronicMigraine Disorders
- Interventions
- Behavioral: Digital CBT-IBehavioral: Sleep Hygiene Education
- Registration Number
- NCT05244889
- Lead Sponsor
- University of Strathclyde
- Brief Summary
The overall aims of the study are:
Aim 1: Estimate effect sizes: To estimate the effects of dCBT-I on insomnia symptoms compared to a control group (sleep hygiene education) and estimate the relationship between changes in insomnia symptoms and the reduction in migraines.
Aim 2: Explore mechanisms of change: To explore the mechanisms underlining the change in migraine symptoms.
Aim 3: Assess barriers to conducting a full-scale RCT: To collect data on recruitment pace and dropouts in both groups, which will help refine the methodology and maximise uptake and retention of a full-scale randomised control trial (RCT). The investigators will conduct qualitative interviews with a select number of participants and practitioners to identify motivators/barriers in uptake of a digitalised version of CBT-I.
- Detailed Description
Chronic migraine (CM) is a debilitating condition that places a direct burden worth £150 million on the NHS per year. Previous research has shown that insomnia is a risk factor for migraines. The investigators hypothesise that two modifiable behaviours explain this relationship between insomnia and migraines: daytime napping and nocturnal light exposure. To cope with the migraines, individuals will nap during the day, reducing the homeostatic drive for sleep at night and delaying sleep onset. This inability to fall asleep potentially increases exposure to evening bright light, delaying the release of the hormone melatonin and reducing sleep quality. Poor sleep in turn is a trigger for migraines, which creates a vicious cycle of migraines and poor sleep. The investigators believe that these behavioural mechanisms are valid targets for treatment and are explicitly addressed in Cognitive Behaviour Therapy for insomnia (CBT-I). Digital versions of CBT-I (dCBT-I) offer a scalable solution to the problem of limited access to CBT-I. This research group has demonstrated the feasibility, acceptability and preliminary efficacy of dCBT-I in an uncontrolled proof-of concept study. Utilising randomised control trial (RCT) methodology, the investigator's aim now is to evaluate the effectiveness of dCBT-I for improving insomnia and migraines in patients with chronic migraines. The second aim is to probe mechanism of change and to test the hypotheses that behavioural markers such as daytime napping and evening light exposure can reduce insomnia symptoms leading to an improvement in migraines. Prior to progressing to a full-scale RCT, the investigators require a feasibility RCT, to refine the methodology. The investigators propose to recruit individuals who meet criteria for CM and insomnia, directly referred from two neurology clinics, who will act as clinical recruiters. Eighty-eight participants will be randomised either to a dCBT-I group or to sleep hygiene education (SHE) control group. The main outcomes are insomnia and migraine days and will be collected at post-treatment, and long-term effects will be assessed at month 6.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 88
- Women age 18 and above
- Insomnia, satisfied by a total score ≥ 11 on the insomnia severity index (ISI)
- Headache ≥ 15 days per month, ≥ 12 months and meet criteria for migraine with/without aura on ≥ 8 days per month, ≥ 12 months
- Medical condition that is unstable, requires immediate treatment, or is judged to interfere with the protocol, including other pain conditions such as chronic low back pain and fibromyalgia and also sleep disorders such as untreated sleep apnoea or parasomnias.
- Psychiatric condition that is judged to interfere with the study protocol including substance abuse, psychotic disorder, cognitive disorder, current suicidal ideation, or any uncontrolled psychiatric conditions that require immediate treatment
- Regular use of illegal substances
- Women who are pregnant or breastfeeding
- Shiftworkers
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Digital CBT-I Digital CBT-I After assignment to dCBT-I, participants will complete a baseline assessment of their sleep, migraines and other outcomes and complete a 30-day sleep and headache diary, and wear an actigraphy device for 7 days to record their sleep and light exposure. They will then be given access to the 6-session dCBT-I programme. At month 1, participants will wear an actigraph device for 1 week.. At month 3 participants will complete a 30-day post-treatment assessment including a sleep and headache diary and the same battery of questionnaires as during the baseline assessment. A subset of participants (and providers) will be invited to participate in an interview about uptake of dCBT-I. At month 6, all participants will complete follow-up questionnaires (similar to baseline and post-treatment questionnaires) and one last 30-day assessment of sleep and headaches and wear a 7-day actigraphy device. Sleep Hygiene Education (SHE) Sleep Hygiene Education After assignment to SHE, participants will complete a baseline assessment of their sleep, migraines and other outcomes and complete a 30-day sleep and headache diary, and wear an actigraphy device for 7 days to record their sleep and light exposure. They will then be given access to the 6-session SHE programme. At month 1, participants will wear an actigraph device for 1 week.. At month 3 participants will complete a 30-day post-treatment assessment including a sleep and headache diary and the same battery of questionnaires as during the baseline assessment. A subset of participants (and providers) will be invited to participate in an interview about uptake of SHE. At month 6, all participants will complete follow-up questionnaires (similar to baseline and post-treatment questionnaires) and one last 30-day assessment of sleep and headaches and wear a 7-day actigraphy device.
- Primary Outcome Measures
Name Time Method Change in Migraine Days Posttreatment (3 months after intervention starts). The change in migraine days (measured with the headache diary) from baseline to posttreatment
Light exposure Mid treatment (Month 1-2 of study) Light exposure measured through an actigraphy device
Recruitment rate Monthly throughout study completion How many participants have been recruited per month
Barriers and Facilitators to Engagement with the protocol Post-treatment (3 months after the intervention started) Measured through qualitative interviews/focus groups
Change in Insomnia Severity Posttreatment (3 months after intervention starts). The change in insomnia (measured with the Insomnia Severity Index - ISI) from baseline to posttreatment. The ISI is scored from 0 to 28, where a higher score indicates more severe insomnia severity.
Retention rate Through study completion, up to 3 years How many participants have dropped out
Naps Mid treatment (Month 1-2 of study) Number (N) of naps
- Secondary Outcome Measures
Name Time Method Adverse Events Through study completion, up to 3 years Adverse Events
Medication use Post-treatment (3 months after the intervention started) Captured through headache diaries
Sleepiness Post-treatment (3 months after the intervention started) Measured with Epworth Sleepiness Scale
Fatigue Post-treatment (3 months after the intervention started) Measured with Flinders Fatigue Scale (FFS)
Treatment Satisfaction Post-treatment (3 months after the intervention started) Measured through in house post-treatment satisfaction questionnaire
Migraine Disability Post-treatment (3 months after the intervention started) Measured with Migraine Disability Assessment (MIDAS) questionnaire
Cost-utility Post-treatment (3 months after the intervention started) Measured with the EQ-5D, health-related quality of life, from which quality adjusted life years (QUALY) can be obtained. This will allow us to calculate cost-utility.
Depression and Anxiety Post-treatment (3 months after the intervention started) Captured with the Four-Item Patient Health Questionnaire (PHQ-4) for Anxiety and Depression
Trial Locations
- Locations (2)
Walton Centre, Liverpool
🇬🇧Liverpool, United Kingdom
Glasgow
🇬🇧Glasgow, United Kingdom